Gene editing has long promised a bespoke future, yet the economics of "n-of-1" medicine—treatments designed for a single individual—have remained prohibitively expensive. For those suffering from ultra-rare genetic conditions, the science often exists, but the market does not. The traditional clinical trial model, built for mass-market pharmaceuticals, creates a financial bottleneck that leaves thousands of potential cures confined to the laboratory.
A new framework for trialing these therapies aims to dismantle this barrier. By standardizing the delivery mechanism and the regulatory pathway while swapping out only the specific genetic "payload," researchers can treat various rare diseases under a unified trial structure. This modular approach treats the CRISPR system as a platform rather than a series of disconnected, individual drugs, streamlining the path from design to delivery.
This shift could finally make the production of personalized therapies an economically viable prospect. If the regulatory and manufacturing burdens are shared across a "basket" of diseases, the per-patient cost of gene editing drops significantly. For the thousands of people living with conditions currently overlooked by major pharmaceutical firms, the transition from experimental curiosity to accessible medicine may finally be within reach.
With reporting from Nature News.
Source · Nature News
